Calf diarrhea due to infection by enterotoxigenic Escherichia coli was treated by administration of glycoprotein glycans derived from bovine plasma. The glycan moieties of the nonimmunoglobulin fraction of plasma mimicked the oligosaccharide moiety of intestinal receptors recognized by K99 pili. These glycoprotein glycans inhibited adhesion of E. coli K99+ ST' to erythrocyte glycoconjugates in vitro, and they protected colostrum-deprived newborn calves against lethal doses of enterotoxigenic E. coli (1010 bacteria). Adhesion of bacteria to the intestines (duodenum, jejunum, and ileum) was significantly reduced (by 2 orders of magnitude) in treated calves.
The pathogenicity of enterotoxigenic Escherichia coli (ETEC) in infectious diarrhea in calves is due, in large part, to the action of enterotoxins (37) . However, it is now known that adhesion of bacteria to the host also plays an important role in bacterial virulence (34) . Adhesion of bacteria is an early process in the development of an infection which involves binding of bacterial lectins, such as K99, F41, and FY pili (10, 11, 18) , to intestinal glycoconjugate receptors.
Various sialoconjugates have been proposed as receptor sites for K99 pili. The carbohydrate moiety of the sheep erythrocyte receptor appears to resemble ganglioside GM2: GaINAc(pl, [NeuAc((a2-3)]Gal(p1-4)Glc(,1-l)Cer (17) .
K99 pili also recognize the oligosaccharide NeuAc(a2-3) Gal(, [1] [2] [3] [NeuAc(a2-6)]GalNAc of human erythrocyte glycophorin A (4, 23) , and NeuGc(a2-3)Galp(P1-4)Glc(1-1) has been identified in horse erythrocytes (32, 36) . These structures have the minimal characteristics of receptors used by pathogenic agents to adhere to intestinal epithelium.
Treatment of bacterial infections by competitive inhibition of bacterium-receptor interactions (20, 21, 29, 41) or toxinreceptor interactions (20, 33, 40) has been proposed. We have demonstrated in vitro that various bovine plasma glycoproteins inhibit adhesion of ETEC to sheep erythrocytes (27) and mucosal glycoproteins (28) . The present study was designed to confirm these in vitro results in vivo. The effect of inhibition of bacterial adhesion by plasma glycoprotein glycans was The presence of anti-E. coli K99 antibodies was tested by specific agglutination of several E. coli strains (27) (Leitz) . Glycoprotein glycan preparations (0.25 to 5 mg/ml in phosphate-buffered saline) were then added to the adhesion system, and inhibition was assessed after 15 min of incubation.
Excretion of the challenge strain. Calves 1 and 2, which received 2 liters of colostrum each, and colostrum-deprived calf 3 were infected within 6 h of birth with 1010 E. coli organisms. They were treated with antiadhesins as described above (500 mg/day). One 12-h-old calf (calf 4) given colostrum to check survival without treatment (19, 25) was challenged with the same dose of E. coli. Feces were collected from both groups during 50 days, and pathogenic bacterial populations were measured. All calves were fed milk during the observation period.
RESULTS
Evaluation of the inhibitory capacity of glycoprotein glycans. The inhibitory capacities of the different molecular species of bovine blood antiadhesin preparations were determined by hemagglutination assays with a reference strain (E. coli B41).
Defibrinated plasma was separated into three fractions by ion-exchange chromatography. G2 immunoglobulins were recovered in fraction I (99.5%); fraction II was composed of P2 and IgGi (52%), ,1 (36.5%), and a globulins (10%); and fraction III contained albumin (71.5%), a globulins (20%), and ,2 and y globulins (8.5%). The presence of anti-E. coli antibodies and anti-K99 antibodies in bovine plasma was checked by using several strains of E. coli bearing K99 pili (27) . Agglutination was observed for serum dilutions of 1/32 and 1/64, depending on the strain, and at dilutions of 1/320
for fraction I and 1/160 for fraction II.
Inhibition of MRHA (80% and 60% for fractions I and II, respectively) due to the presence of anti-K99 immunoglobulins or, more generally, anti-E. coli antibodies in fractions I and II (data not shown) disappeared after proteolysis (Fig.  1) . The oligosaccharide structures of these immunoglobulins ( Fig. 2) 13.6 ,ug of glycan per mg of peptide), and III (U; 13.6 ,ug of glycan per mg of peptide), separated on DEAE-Trisacryl were hydrolyzed by 1% subtilisin A at 50°C. The degree of hydrolysis was 35 ± 2% for the three fractions after 5 h of hydrolysis. Most of the glycopeptides had mean molecular weights below 104. The inhibitory capacities were measured by using a hemagglutination test (fraction I was at 0.25 mg/ml, and II and III were at 0.1 mg/ml of peptide). Bovine serum albumin (O) hydrolyzed under the same conditions was used as a control to measure the abilities of peptides to inhibit K99-mediated hemagglutination (at 10 mg/ml).
Pathogenicity of the bacterial strain. Since a variety of bacterial properties, such as growth, chemotaxis, resistance to host defenses, and toxin production, play a role in virulence, we used a strain of E. coli that is representative of bovine pathology observed in the field. To determine the pathogenicity of this strain in experimental colibacillosis, calves were inoculated with bacteria (107 to 1010 organisms) within 8 h of birth. Bacterial colonization remained constant in the three sections of small intestine, and the infection was accompanied by fatal diarrhea ( 10-1-16, 1987) .
Clinical course of infection after inoculation. Various functional disorders related to the diarrheal syndrome and the intensity of the infection were observed. In infected and untreated calves (controls), there was considerable loss of electrolytes due to the action of enterotoxins (Fig. 3) . The pH of feces increased from a normal value of 5.5 to over 8 (Fig. 4) , and hyperkalemia was consistently observed in severely dehydrated animals (Fig. 5) . Diarrhea was less severe in calves treated with the glycoprotein glycan preparations (Table 2 ). Electrolyte loss was reduced (Fig. 3) , and fecal pH returned to normal within 2 to 3 days (Fig. 4) . Potassium levels in blood remained normal in these animals (Fig. 5) . Treated calves survived the infection and were cured within 72 h in most cases (11 of 13 or 84.6%). One calf treated at a later time, 5 to 6 h after the onset of diarrhea, presented signs of dehydration and died.
Adhesion of ETEC to intestinal mucosa. A control group was not readily constituted, since most of the untreated calves died within 41 to 62 h postchallenge (Tables 1 and 2) . Further experiments were performed with calves which received other types of treatment. Unfortunately, oral fluid therapy in two calves did not prevent death under the severe conditions of the experiment (colostrum-deprived calves inoculated with 1010 bacteria).
The beneficial effect of the treatment could, however, have been due to rehydration from the cocktail of carbohydrates and amino acids present in the antiadhesive material. To rule out this possibility, we compared the compositions of six commercial oral rehydratants and antiadhesin preparations. These preparations differed considerably in salt, sugar, and fluid contents. Only the quantities of amino acids (linked or free) were comparable (Fig. 6) . We also administered total plasma hydrolysates without conservation of oligosaccharide structures (27) (0.5 and 5 mg of amino acid equivalents per ml, respectively), whereas the antiadhesin preparations inhibited MRHA by 50 ± 3 and 96 ± 4%. Furthermore, the calves treated with these hydrolysates died with symptoms of diarrhea within 62 h of bacterial inoculation. No corresponding drop in the number of E. coli that adhered to mucosa was observed ( Table 3) . Administration of antiadhesin preparations led to a fall in the number of adherent bacteria in the three parts of the small intestines. Extensive use of antibiotics has contributed to the development of antibiotic-resistant E. coli strains that infect cattle and other animal species (24, 26) . Considerable interest has therefore been shown in immunoprophylaxis against ETEC pili. Pregnant cows may be protected by vaccination and transmission of specific anti-pilus antibodies by colostrum (7, 13) . In some cases, an immunoserocolostrum has been administered (35) . These vaccines and, in general, any agents that affect ETEC adhesion to intestinal mucosa cells reduce the pathogenicity of microorganisms. Among the various substances evaluated in vitro, recent studies have indicated the value of antibiotics at subinhibitory doses (12, 22) or hydrophobic compounds, such as aromatic hydrocarbons (16) . Increased understanding of the virulence of ETEC and other pathogenic agents at the molecular level has led to studies of analogs either of pili and other structures present on infectious agents or of receptors recognized by these structures.
Our results show that experimentally infected animals can be successfully treated by agents which act on the attachment sites of bacterial pili. These nontoxic molecules, obtained from plasma of normal cattle, mimic the glycan moieties of natural receptors. In vitro assays showed that these receptor analogs do not act via an antibody-antigen- The small intestines were carefully unfolded, ensuring that the contents were undisturbed. The ratio was determined from the number of bacteria that formed colonies on Minca medium containing nalidixic acid.
tained bear terminal NeuGc sequences (8) which are not present in IgG glycans (30) . The biantennary glycan structure of bovine transferrin (present in fraction II), which contains only the NeuAc(a2-6)Gal sequence (39), had no inhibitory action. However, the non-immune system Nglycosylated glycoproteins (8, 9) bearing the minimal sequence NeuGc(a2-3)Gal of the receptor site ( Fig. 2 ) did inhibit adhesion of K99+ E. coli organisms. This is in agreement with the established structures of the K99 pilus receptor (4, 17, 23, 33, 36) . It should be noted that the glycoprotein glycans in fraction III may be partially masked by protein structures. Hydrolysis would thus tend to reveal their activity. The in vivo data were consistent with the in vitro results. Nevertheless, we could not establish with confidence that (28) .
In the experiments reported here, the effective doses that provided a cure in less than 72 h ranged from 1.5 to 3 g per calf. These differences were due, at least in part, to The curative effect of the glycans was observed in a situation in which host defense mechanisms were not yet operative. The newborn calves used were colostrum deprived and thus did not benefit from maternal immunoglobulins. Our finding that relatively small amounts of glycan hydrolysates exerted a protective action in heavily infected calves is in agreement with the results of Otness et al., who showed that nonimmunological components of milk, even in trace amounts, may protect against certain gastrointestinal infections in rabbits (33) .
These natural receptor analogs could be digested, but calf intestine appears to have only weak glycolytic activity. Amylase activity is detected, but there is no oligoglucosidase (6). Although we have no direct evidence of the evolution of these receptor analogs in the digestive tract, preliminary studies using radiolabeled analogs indicated the absence of degradation in unweaned mice (unpublished data).
Treatment of ETEC diarrhea in neonatal calves by bacterial receptor analogs provides a new and promising approach to early therapy, either alone or in combination with other treatments. Plasma-derived glycoprotein glycans of the Nacetyllactosamine type (Fig. 2) contain sugar sequences which may be the major determinants of the recognition sites in the digestive tract for various bacterial lectins (9) . Bacterial adhesins (pili, flagella, and external membrane proteins) are known to have specific affinities for a variety of glycan structures (26a, 29, 32 These analogs are simple to use (oral administration) and are derived from a cheap raw material (blood plasma). They could therefore be used in other animal species, as well as humans, in situations in which bacterial colonization and adhesion depend on the recognition of specific glycans in the digestive tract. 
